Summary
- Main use
- Correction of fluid and nutritional deficiencies (electrolytes, amino acids, etc.) in premature infants
- Who uses it
- Adults · Children
- Adult dosage
- Determine the dose according to the patient's condition, energy expenditure, body weight, age, metabolic capacity, and additional calories or protein supplied orally or via the gastrointestinal tract. Do not exceed the maximum recommended dose. Because the composition of the multi-chamber bag is fixed, it may not meet all of the patient's nutritional requirements at the same time. There may be clinical situations in which the patient requires nutrients in proportions different from the fixed composition. Determine the maximum recommended infusion rate per hour and daily dose according to the components. If any one component is administered at its maximum dose, the maximum daily dose of this medicine has been reached. The maximum recommended infusion rate per hour and daily dose are as follows. Three-chamber admixture (300 mL) Maximum infusion rate (mL/kg/hour) 6.4 Equivalent to: Amino acids (g/kg/hour) 0.20 Glucose (g/kg/hour) 0.85 Lipids (g/kg/hour) 0.16 Maximum infusion volume (mL/kg/day) 127.9 Equivalent to: Amino acids (g/kg/day) 4.0 Glucose (g/kg/day) 17.1 Lipids (g/kg/day) 3.2 Osmolarity (approximately mOsm/L) 1150 Because this undiluted medicine has high osmolarity, it can be administered only through a central vein. However, sufficient dilution of this medicine with water for injection lowers its osmolarity, making peripheral intravenous infusion possible. Gradually increase the infusion rate during the first hour of administration. When discontinuing this medicine, gradually decrease the infusion rate during the 1 hour before stopping the infusion. Adjust the infusion rate taking into account the dose to be administered, daily intake, and infusion time. Cyclic infusions should be managed according to the patient's metabolic tolerance. Parenteral nutrition therapy may be continued for as long as the patient's clinical condition requires. This medicine contains electrolytes. Electrolytes may be supplemented, and vitamins and trace elements may be added, according to the physician's judgment and the patient's clinical needs (see Precautions for Use, “10. Precautions for Administration”).
- Children's dosage
- This medicine may not be suitable for some premature infants because the patient's clinical condition may require administration of an individualized formulation to meet the patient's specific needs, as assessed by the clinician. For premature infants, continuous intravenous administration over 24 hours is usually recommended. However, the same bag should not be infused for more than 24 hours.
Ingredients
- L-Alanine0.466g / 100mL
- L-Arginine0.489g / 100mL
- L-Aspartic Acid0.35g / 100mL
- L-Cysteine0.11g / 100mL
- L-Glutamic Acid0.583g / 100mL
- Glycine0.233g / 100mL
- L-Histidine0.221g / 100mL
- L-Isoleucine0.39g / 100mL
- L-Leucine0.583g / 100mL
- L-Lysine Monohydrate0.72g / 100mL
- L-Methionine0.14g / 100mL
- L-Ornithine Hydrochloride0.185g / 100mL
- L-Phenylalanine0.245g / 100mL
- L-Proline0.175g / 100mL
- L-Serine0.233g / 100mL
- Taurine0.035g / 100mL
- L-Threonine0.216g / 100mL
- L-Tryptophan0.117g / 100mL
- L-Tyrosine0.045g / 100mL
- L-Valine0.443g / 100mL
- Potassium Acetate0.383g / 100mL
- Calcium Chloride Hydrate0.345g / 100mL
- Magnesium Acetate Tetrahydrate0.063g / 100mL
- Sodium Glycerophosphate Hydrate0.615g / 100mL
- Glucose Monohydrate55g / 100mL
- Purified Olive Oil12.5g / 100mL
- Refined Soyabean Oil2.5g / 100mL
- Importer
- .
Efficacy & effects
Correction of fluid and nutritional deficiencies (electrolytes, amino acids, etc.) in premature infants
View approved original textHide original text
This medicine helps maintain the necessary nutritional status by providing water, electrolytes, amino acids, and calories to premature infants who have difficulty with oral or enteral nutrition. It primarily provides essential nutrients for the growth and development of premature infants directly via the intravenous route, thereby preventing nutritional deficiencies. This supports the healthy growth of premature infants and reduces complications arising from nutritional imbalances.
Dosage and Administration
Adult dosage
Determine the dose according to the patient's condition, energy expenditure, body weight, age, metabolic capacity, and additional calories or protein supplied orally or via the gastrointestinal tract. Do not exceed the maximum recommended dose. Because the composition of the multi-chamber bag is fixed, it may not meet all of the patient's nutritional requirements at the same time. There may be clinical situations in which the patient requires nutrients in proportions different from the fixed composition. Determine the maximum recommended infusion rate per hour and daily dose according to the components. If any one component is administered at its maximum dose, the maximum daily dose of this medicine has been reached. The maximum recommended infusion rate per hour and daily dose are as follows. Three-chamber admixture (300 mL) Maximum infusion rate (mL/kg/hour) 6.4 Equivalent to: Amino acids (g/kg/hour) 0.20 Glucose (g/kg/hour) 0.85 Lipids (g/kg/hour) 0.16 Maximum infusion volume (mL/kg/day) 127.9 Equivalent to: Amino acids (g/kg/day) 4.0 Glucose (g/kg/day) 17.1 Lipids (g/kg/day) 3.2 Osmolarity (approximately mOsm/L) 1150 Because this undiluted medicine has high osmolarity, it can be administered only through a central vein. However, sufficient dilution of this medicine with water for injection lowers its osmolarity, making peripheral intravenous infusion possible. Gradually increase the infusion rate during the first hour of administration. When discontinuing this medicine, gradually decrease the infusion rate during the 1 hour before stopping the infusion. Adjust the infusion rate taking into account the dose to be administered, daily intake, and infusion time. Cyclic infusions should be managed according to the patient's metabolic tolerance. Parenteral nutrition therapy may be continued for as long as the patient's clinical condition requires. This medicine contains electrolytes. Electrolytes may be supplemented, and vitamins and trace elements may be added, according to the physician's judgment and the patient's clinical needs (see Precautions for Use, “10. Precautions for Administration”).
Children's dosage
This medicine may not be suitable for some premature infants because the patient's clinical condition may require administration of an individualized formulation to meet the patient's specific needs, as assessed by the clinician. For premature infants, continuous intravenous administration over 24 hours is usually recommended. However, the same bag should not be infused for more than 24 hours.
Precautions
This medicine requires caution as it may increase free fatty acid levels in the blood when administered to premature and low-birth-weight infants. In particular, fatal side effects such as pulmonary vascular fat accumulation have been reported in premature infants with severe respiratory disease, so it should be avoided. This medicine should not be administered to patients with allergies to eggs, soybeans, peanuts, congenital amino acid metabolism disorders, abnormal serum electrolyte levels, patients using Ceftriaxone, or those with severe hyperglycemia and hyperlipidemia. In patients with pulmonary edema, heart failure, renal failure, or severe liver failure, careful administration is needed, while closely monitoring fluid and electrolyte status. Patients with insufficient metabolic capacity or endocrine and metabolic disorders also require caution. During administration, there is a possibility of adverse reactions such as hypophosphatemia, hyperglycemia, hypercalcemia, hypertriglyceridemia, cholestasis, etc., thus regular testing and observation are necessary. Particularly, administering intravenously without adequate dilution can lead to severe side effects such as skin necrosis or soft tissue damage. If an allergic reaction occurs, administration should be immediately discontinued, and caution should be exercised as it contains corn-derived glucose, which may affect patients with corn allergies. Co-administration with Ceftriaxone in premature infants is prohibited due to the risk of pulmonary embolism; therefore, excessive addition of calcium and phosphate should be avoided. There is a risk of infection and sepsis during administration, so catheter management and aseptic techniques are important, and awareness of the possibility of metabolic complications such as fat overload syndrome and refeeding syndrome is also necessary. In case of overdose, symptoms such as nausea, vomiting, electrolyte imbalances, fluid overload, and acidosis may occur; therefore, immediate cessation of administration and appropriate treatment are required. This medicine is recommended for administration via central venous access, and the solution's condition and the presence of any precipitates in the infusion set and catheter should be checked before administration. Due to insufficient safety data for pregnant and nursing women, it should be administered cautiously under the judgment of a physician when necessary. Additionally, some components of this medication may affect certain clinical test results, so it is better to adjust the timing of tests.
Side effects
- Hypophosphatemia
- hyperglycemia
- hypercalcemia
- hypertriglyceridemia
- hyperlipidemia
- hyponatremia
- cholestasis
- skin necrosis
- soft tissue damage
- extravasation
Show 25 moreCollapse
- fat overload syndrome
- pulmonary vascular precipitate
- nausea
- vomiting
- tremors
- electrolyte disturbances
- fluid overload
- signs of acidosis
- diabetes
- hyperosmolar syndrome
- fever
- sweating
- chills
- headache
- skin rash
- dyspnea
- hepatic steatosis
- hepatomegaly
- impaired liver function
- anemia
- leukopenia
- thrombocytopenia
- coagulopathy
- central nervous system manifestations
- coma
Not everyone experiences these, and they can vary from person to person.
Storage
This medicine should be stored in a sealed container to prevent contact with air, and the storage temperature should be maintained between 1 to 25 degrees Celsius. Additionally, care should be taken not to freeze the medicine.
Appearance and packaging
Appearance
The amino acid solution and the sugar solution are colorless to pale yellow transparent liquids, while the fat solution is a homogeneous cloudy liquid separated into three compartments by two membranes in a single transparent plastic bag for infusion.
Package unit
300 mL (Amino acid solution 160 mL, Sugar solution 80 mL, Fat solution 60 mL) / Bag
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.